Cargando…

Transcriptomic Signatures of MSI-High Metastatic Colorectal Cancer Predict Efficacy of Immune Checkpoint Inhibitors

PURPOSE: Microsatellite instability (MSI) is currently the only predictive biomarker of efficacy of immune checkpoint inhibitors (ICI) in metastatic colorectal cancers (mCRC). However, 10% to 40% of patients with MSI mCRC will experience a primary resistance to ICI. EXPERIMENTAL DESIGN: In two cohor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gallois, Claire, Landi, Matteo, Taieb, Julien, Sroussi, Marine, Saberzadeh-Ardestani, Bahar, Cazelles, Antoine, Lonardi, Sara, Bergamo, Francesca, Intini, Rossana, Maddalena, Giulia, Pietrantonio, Filippo, Corti, Francesca, Ambrosini, Margherita, Martinetti, Antonia, Germani, Marco Maria, Boccaccio, Chiara, Vetere, Guglielmo, Mouillet-Richard, Sophie, de Reynies, Aurélien, Sinicrope, Frank A., Cremolini, Chiara, Laurent-Puig, Pierre
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2023
Materias:	Translational Cancer Mechanisms and Therapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10502457/ https://www.ncbi.nlm.nih.gov/pubmed/37439810 http://dx.doi.org/10.1158/1078-0432.CCR-22-3964

Ejemplares similares

Association of immune-related adverse events with the outcomes of immune checkpoint inhibitors in patients with dMMR/MSI-H metastatic colorectal cancer
por: Nasca, Vincenzo, et al.
Publicado: (2023)

Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers
por: Fucà, Giovanni, et al.
Publicado: (2022)

Negative Ultraselection of Patients With RAS/BRAF Wild-Type, Microsatellite-Stable Metastatic Colorectal Cancer Receiving Anti–EGFR-Based Therapy
por: Randon, Giovanni, et al.
Publicado: (2022)

Synchronous Neoplasia Rates at Colonoscopic Diagnosis of Early-Onset vs Average-Onset Colorectal Cancer
por: Emiloju, Oluwadunni E., et al.
Publicado: (2023)

Prognostic impact of early tumor shrinkage and depth of response in patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors
por: Fucà, Giovanni, et al.
Publicado: (2021)

Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO
por: Rossini, Daniele, et al.
Publicado: (2020)

Comparative lipid profiling of murine and human atherosclerotic plaques using high-resolution MALDI MSI
por: Khamehgir-Silz, Pegah, et al.
Publicado: (2021)

Nomogram to predict the outcomes of patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors
por: Pietrantonio, Filippo, et al.
Publicado: (2021)

Treatment with checkpoint inhibitors in a metastatic colorectal cancer patient with molecular and immunohistochemical heterogeneity in MSI/dMMR status
por: Loupakis, Fotios, et al.
Publicado: (2019)

Transcriptomic Profiling of MSI-H/dMMR Gastrointestinal Tumors to Identify Determinants of Responsiveness to Anti–PD-1 Therapy
por: Chida, Keigo, et al.
Publicado: (2022)

Immunotherapy in Gastrointestinal Cancers
por: Procaccio, Letizia, et al.
Publicado: (2017)

The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients
por: Battaglin, Francesca, et al.
Publicado: (2018)

FOLFOXIRI plus bevacizumab in the treatment of metastatic colorectal cancer patients with unresectable liver metastases
por: Antoniotti, Carlotta, et al.
Publicado: (2022)

BRAF (V600E)/RAS Mutations and Lynch Syndrome in Patients With MSI-H/dMMR Metastatic Colorectal Cancer Treated With Immune Checkpoint Inhibitors
por: Colle, Raphael, et al.
Publicado: (2023)

Reinduction of an Anti-EGFR-based First-line Regimen in Patients with RAS Wild-type Metastatic Colorectal Cancer Enrolled in the Valentino Study
por: Fucà, Giovanni, et al.
Publicado: (2022)

Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical study
por: Cremolini, Chiara, et al.
Publicado: (2017)

Different Vancomycin-Intermediate Staphylococcus aureus Phenotypes Selected from the Same ST100-hVISA Parental Strain
por: Di Gregorio, Sabrina, et al.
Publicado: (2017)

Pilot Screening to Determine Antimicrobial Synergies in a Multidrug-Resistant Bacterial Strain Library
por: Kim, Si-Hyun, et al.
Publicado: (2016)

Genomic Characterization of Nonclonal mcr-1-Positive Multidrug-Resistant Klebsiella pneumoniae from Clinical Samples in Thailand
por: Srijan, Apichai, et al.
Publicado: (2018)

Morphological and Biological Characteristics of Staphylococcus aureus Biofilm Formed in the Presence of Plasma
por: Sato, Ayami, et al.
Publicado: (2019)

Activity of Cefiderocol Against Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii Endemic to Medical Centers in New York City
por: Iregui, Alejandro, et al.
Publicado: (2020)

Resistome and a Novel bla(NDM-1)-Harboring Plasmid of an Acinetobacter haemolyticus Strain from a Children's Hospital in Puebla, Mexico
por: Bello-López, Elena, et al.
Publicado: (2019)

Alliance of Efflux Pumps with β-Lactamases in Multidrug-Resistant Klebsiella pneumoniae Isolates
por: Maurya, Navdezda, et al.
Publicado: (2019)

Mechanisms of Reduced Susceptibility to Cefiderocol Among Isolates from the CREDIBLE-CR and APEKS-NP Clinical Trials
por: Nordmann, Patrice, et al.
Publicado: (2022)

Antimicrobial Resistance and Molecular Characterization of Gene Cassettes from Class 1 Integrons in Escherichia coli Strains
por: Li, Wanxiang, et al.
Publicado: (2022)

Escherichia coli ST471 Producing VIM-4 Metallo-β-Lactamase in Colombia
por: Rada, Ana Mercedes, et al.
Publicado: (2022)

Application of a Kinetic Model for Studying the Spatial Spread of COVID-19
por: Aristov, V. V., et al.
Publicado: (2022)

Genetic and Phenotypic Characterization of the First Canadian Case of Ambler Class A Carbapenemase FRI-8
por: Mataseje, Laura F., et al.
Publicado: (2023)

The Capsule Increases Susceptibility to Last-Resort Polymyxins, but Not to Other Antibiotics, in Klebsiella pneumoniae
por: D’Angelo, Francesca, et al.
Publicado: (2023)

Should immunohistochemical expression of mismatch repair (MMR) proteins and microsatellite instability (MSI) analysis be routinely performed for poorly differentiated colorectal neuroendocrine carcinomas?
por: Luong, Tu Vinh, et al.
Publicado: (2020)

TremelImumab and Durvalumab Combination for the Non-OperatIve Management (NOM) of Microsatellite InstabiliTY (MSI)-High Resectable Gastric or Gastroesophageal Junction Cancer: The Multicentre, Single-Arm, Multi-Cohort, Phase II INFINITY Study
por: Raimondi, Alessandra, et al.
Publicado: (2021)

AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer
por: Antoniotti, Carlotta, et al.
Publicado: (2020)

Immune Checkpoint Inhibitors in pMMR Metastatic Colorectal Cancer: A Tough Challenge
por: Marmorino, Federica, et al.
Publicado: (2020)

Colorectal Carcinogenesis: MSI-H Versus MSI-L
por: Pawlik, Timothy M., et al.
Publicado: (2004)

Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials
por: Cremolini, Chiara, et al.
Publicado: (2018)

BRAF-mutated metastatic colorectal cancer between past and future
por: Cremolini, Chiara, et al.
Publicado: (2015)

A proof of concept for targeting the PrP(C) - Amyloid β peptide interaction in basal prostate cancer and mesenchymal colon cancer
por: Mouillet-Richard, Sophie, et al.
Publicado: (2022)

Downregulation of mitochondrial complex I induces ROS production in colorectal cancer subtypes that differently controls migration
por: Bastin, Jean, et al.
Publicado: (2023)

CK7 and consensus molecular subtypes as major prognosticators in (V600E)BRAF mutated metastatic colorectal cancer
por: Loupakis, Fotios, et al.
Publicado: (2019)

Association Between Survival and Metastatic Site in Mismatch Repair–Deficient Metastatic Colorectal Cancer Treated With First-line Pembrolizumab
por: Saberzadeh-Ardestani, Bahar, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_9lgvj6ebshoqji10ea8h7uumjd